| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8725085 | Clinical Gastroenterology and Hepatology | 2018 | 27 Pages |
Abstract
In a prospective study, we found pioglitazone to be effective in patients with and without type 2 diabetes. However, pioglitazone reduced liver fibrosis and increased adipose tissue insulin sensitivity at significantly greater levels in patients with type 2 diabetes than in patients with prediabetes. Further studies are needed to determine the mechanisms by which pioglitazone reduces liver disease in patients with type 2 diabetes. ClinicalTrials.gov: NCT00994682.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Fernando Bril, Srilaxmi Kalavalapalli, Virginia C. Clark, Romina Lomonaco, Consuelo Soldevila-Pico, I-Chia Liu, Beverly Orsak, Fermin Tio, Kenneth Cusi,